08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Avanir Chronicles

Avanir Chronicles Avanir chroniclesThe $17 takeout price Otsuka Pharmaceutical Co. Ltd. will pay for Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) is only a 13% premium to the neurology play's close the day before the $3.5 billion deal...
07:00 , Aug 12, 2013 |  BioCentury  |  Strategy

FibroGen's globetrotting

Seven years after its last major deal, FibroGen Inc. has now carved up worldwide rights to FG-4592 via its new deal with AstraZeneca plc . A key task for FibroGen is now to execute in...
07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Company News

Astellas, Sanofi deal

Astellas and Sanofi dissolved their 49/51 sanofi-aventis Yamanouchi Pharmaceutical Inc. JV. The pharmas said the JV, which was established in 1986 and had exclusive rights to commercialize Sanofi's cardiovascular drug Milrila milrinone in Japan, was...
08:00 , Mar 8, 2010 |  BioCentury  |  Strategy

OSI's Last Stand

OSI Pharmaceuticals Inc. has made two strategic decisions in the last five years that investors didn't like. As a result, it would not be surprising if they refuse to back the company's independence following last...
08:00 , Dec 21, 2009 |  BioCentury  |  Finance

Ebb & Flow

The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc . (Tokyo:4503) has led to big payoffs in the last two weeks for Calixa Therapeutics Inc. and...
08:00 , Dec 14, 2009 |  BioCentury  |  Finance

Ebb & Flow

Investors in oncology company Gloucester Pharmaceuticals Inc. are looking at a 3.5X-6.5X return on an acquisition by Celgene Corp. (NASDAQ: CELG), making it a model for how to execute in-licensing and keep costs under control....
07:00 , Sep 7, 2009 |  BioCentury  |  Strategy

A small, private affair

In 2004, Gloucester Pharmaceuticals Inc. took a bet on a small molecule HDAC inhibitor that Fujisawa Co. Ltd. was divesting. That bet looks to have paid off, as FDA 's the Oncologic Drugs Advisory Committee...
07:00 , Aug 17, 2009 |  BioCentury  |  Emerging Company Profile

Calixa: Bettering cephalosporin

Calixa Therapeutics Inc. is developing an in-licensed cephalosporin it says is more potent against multi-drug resistant strains of Pseudomonas aeruginosa than all other available beta lactams. The lead compound, CXA-101 , and two follow-ons are...
08:00 , Feb 12, 2009 |  BC Innovations  |  Targets & Mechanisms

New shock treatment

German researchers have found that targeting two G proteins could treat the vascular symptoms of anaphylactic shock while avoiding the cardiovascular side effects of epinephrine, the standard of care. If a selective inhibitor for the...